{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,31]],"date-time":"2026-07-31T14:07:24Z","timestamp":1785506844219,"version":"3.56.0"},"reference-count":27,"publisher":"The Endocrine Society","issue":"8","license":[{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,7,8]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Context<\/jats:title>\n                    <jats:p>Adrenocortical carcinoma (ACC) is a rare, aggressive malignancy with limited treatment options beyond first-line therapy, underscoring the need for effective salvage regimens.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>To evaluate the clinical activity and safety of gemcitabine and oxaliplatin (GemOx) in advanced ACC.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Design<\/jats:title>\n                    <jats:p>Retrospective cohort study conducted from April 2023 to April 2024 with longitudinal follow-up.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Setting<\/jats:title>\n                    <jats:p>Single-center tertiary referral cancer center.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Patients or Other Participants<\/jats:title>\n                    <jats:p>Fourteen patients with histologically confirmed advanced ACC treated with GemOx were included. Patients were heavily pretreated, with a median of 3 prior systemic therapies (range, 2-9); 43% had hormonally functional tumors.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Intervention(s)<\/jats:title>\n                    <jats:p>Gemcitabine (1000\u2005mg\/m2 on days 1 and 8) and oxaliplatin (130\u2005mg\/m2 on day 1) every 3\u2005weeks until disease progression or unacceptable toxicity.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Main Outcome Measure(s)<\/jats:title>\n                    <jats:p>Primary outcomes were progression-free survival (PFS) and overall survival (OS). Secondary outcomes included objective response rate per Response Evaluation Criteria In Solid Tumors 1.1 and treatment-related toxic effects.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>After a median follow-up of 10.7\u2005months (95% CI, 8.5-15.7), median PFS was 3.2\u2005months (95% CI, 0.4-6.0) and OS was 13.0\u2005months (95% CI, 3.6-22.5). Among 13 evaluable patients, 2 (15.4%) achieved partial response, 8 (61.5%) had stable disease, and 3 (23.1%) had progressive disease, yielding a disease control rate of 76.9%. No treatment-related deaths occurred.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>GemOx demonstrated modest clinical activity with manageable safety in heavily pretreated patients with advanced ACC. These findings suggest a potential role for GemOx as a salvage option, though validation in larger prospective studies is needed.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1210\/jendso\/bvag152","type":"journal-article","created":{"date-parts":[[2026,6,30]],"date-time":"2026-06-30T20:48:00Z","timestamp":1782852480000},"source":"Crossref","is-referenced-by-count":0,"title":["Gemcitabine and oxaliplatin combination in patients with advanced adrenocortical carcinoma"],"prefix":"10.1210","volume":"10","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3755-7729","authenticated-orcid":false,"given":"Lily","family":"Chen","sequence":"first","affiliation":[{"name":"Department of Internal Medicine, McGovern Medical School, The University of Texas Health Science Center at Houston , Houston, TX 77030, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9327-9615","authenticated-orcid":false,"given":"Vania","family":"Balderrama-Brondani","sequence":"additional","affiliation":[{"name":"Department of Endocrine Neoplasia and Hormonal Disorders, Division of Internal Medicine, The University of Texas MD Anderson Cancer Center , Houston, TX 77030 , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leonardo P","family":"Marcal","sequence":"additional","affiliation":[{"name":"Department of Abdominal Imaging, The University of Texas MD Anderson Cancer Center , Houston, TX 77030, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5292-3355","authenticated-orcid":false,"given":"Camilo","family":"Jimenez","sequence":"additional","affiliation":[{"name":"Department of Endocrine Neoplasia and Hormonal Disorders, Division of Internal Medicine, The University of Texas MD Anderson Cancer Center , Houston, TX 77030 , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeena","family":"Varghese","sequence":"additional","affiliation":[{"name":"Department of Endocrine Neoplasia and Hormonal Disorders, Division of Internal Medicine, The University of Texas MD Anderson Cancer Center , Houston, TX 77030 , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amishi Y","family":"Shah","sequence":"additional","affiliation":[{"name":"Department of Genitourinary Medical Oncology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center , Houston, TX 77030 , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mouhammed Amir","family":"Habra","sequence":"additional","affiliation":[{"name":"Department of Endocrine Neoplasia and Hormonal Disorders, Division of Internal Medicine, The University of Texas MD Anderson Cancer Center , Houston, TX 77030 , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1915-4491","authenticated-orcid":false,"given":"Matthew T","family":"Campbell","sequence":"additional","affiliation":[{"name":"Department of Genitourinary Medical Oncology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center , Houston, TX 77030 , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"80","published-online":{"date-parts":[[2026,7,1]]},"reference":[{"issue":"10","key":"2026073109214794300_bvag152-B1","doi-asserted-by":"crossref","first-page":"2119","DOI":"10.1093\/annonc\/mdv329","article-title":"Prognostic factors in stage III\u2013IV adrenocortical carcinomas (ACC): an European Network for the Study of Adrenal Tumor (ENSAT) study","volume":"26","author":"Lib\u00e9","year":"2015","journal-title":"Ann Oncol"},{"issue":"2","key":"2026073109214794300_bvag152-B2","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1210\/er.2013-1029","article-title":"Adrenocortical carcinoma","volume":"35","author":"Else","year":"2014","journal-title":"Endocr Rev"},{"issue":"23","key":"2026073109214794300_bvag152-B3","doi-asserted-by":"crossref","first-page":"2189","DOI":"10.1056\/NEJMoa1200966","article-title":"Combination chemotherapy in advanced adrenocortical carcinoma","volume":"366","author":"Fassnacht","year":"2012","journal-title":"N Engl J Med"},{"issue":"2","key":"2026073109214794300_bvag152-B4","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1677\/ERC-09-0281","article-title":"Gemcitabine plus metronomic 5-fluorouracil or capecitabine as a second-\/third-line chemotherapy in advanced adrenocortical carcinoma: a multicenter phase II study","volume":"17","author":"Sperone","year":"2010","journal-title":"Endocr Relat Cancer"},{"issue":"11","key":"2026073109214794300_bvag152-B5","doi-asserted-by":"crossref","first-page":"4323","DOI":"10.1210\/jc.2017-01624","article-title":"Gemcitabine-based chemotherapy in adrenocortical carcinoma: a multicenter study of efficacy and predictive factors","volume":"102","author":"Henning","year":"2017","journal-title":"J Clin Endocrinol Metab"},{"key":"2026073109214794300_bvag152-B6","doi-asserted-by":"crossref","first-page":"1545012","DOI":"10.3389\/fimmu.2025.1545012","article-title":"Therapeutic strategies for adrenocortical carcinoma: integrating genomic insights, molecular targeting, and immunotherapy","volume":"16","author":"Sun","year":"2025","journal-title":"Front Immunol"},{"issue":"1 Suppl 2","key":"2026073109214794300_bvag152-B7","first-page":"25","article-title":"Phase I study of the gemcitabine\/oxaliplatin combination in patients with advanced solid tumors: a preliminary report","volume":"27","author":"Mavroudis","year":"2000","journal-title":"Semin Oncol"},{"issue":"3","key":"2026073109214794300_bvag152-B8","first-page":"227","article-title":"Cellular and molecular pharmacology of oxaliplatin","volume":"1","author":"Raymond","year":"2002","journal-title":"Mol Cancer Ther"},{"issue":"4","key":"2026073109214794300_bvag152-B9","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1038\/sj.bjc.6602966","article-title":"Gemcitabine and oxaliplatin (GEMOX) in gemcitabine refractory advanced pancreatic adenocarcinoma: a phase II study","volume":"94","author":"Demols","year":"2006","journal-title":"Br J Cancer"},{"issue":"6","key":"2026073109214794300_bvag152-B10","doi-asserted-by":"crossref","first-page":"1502","DOI":"10.1002\/cam4.299","article-title":"Cisplatin\/gemcitabine or oxaliplatin\/gemcitabine in the treatment of advanced biliary tract cancer: a systematic review","volume":"3","author":"Fiteni","year":"2014","journal-title":"Cancer Med"},{"issue":"3","key":"2026073109214794300_bvag152-B11","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1093\/annonc\/mdh103","article-title":"Gemcitabine and oxaliplatin (GEMOX) in patients withcisplatin-refractory germ cell tumors: a phase II study","volume":"15","author":"Pectasides","year":"2004","journal-title":"Ann Oncol"},{"issue":"19","key":"2026073109214794300_bvag152-B12","doi-asserted-by":"crossref","first-page":"3428","DOI":"10.1002\/cncr.29517","article-title":"Gemcitabine and oxaliplatin or alkylating agents for neuroendocrine tumors: comparison of efficacy and search for predictive factors guiding treatment choice","volume":"121","author":"Dussol","year":"2015","journal-title":"Cancer"},{"issue":"15","key":"2026073109214794300_bvag152-B13","doi-asserted-by":"crossref","first-page":"3392","DOI":"10.1002\/cncr.24384","article-title":"Gemcitabine and oxaliplatin combination chemotherapy for metastatic well-differentiated neuroendocrine carcinomas","volume":"115","author":"Cassier","year":"2009","journal-title":"Cancer"},{"issue":"2","key":"2026073109214794300_bvag152-B14","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1016\/j.ejca.2010.09.015","article-title":"Phase II study of gemcitabine combined with oxaliplatin in relapsed or refractory paediatric solid malignancies: an innovative therapy for children with Cancer European Consortium Study","volume":"47","author":"Geoerger","year":"2011","journal-title":"Eur J Cancer"},{"key":"2026073109214794300_bvag152-B15","unstructured":"Chen L, Balderrama-Brondani V, Marcal LP, et al \u00a0Supplemental table 1. Clinical characteristics of 14 patients with metastatic adrenocortical carcinoma treated with gemcitabine combined with oxaliplatin. J Endocr Soc. 10.5281\/zenodo.20710842"},{"key":"2026073109214794300_bvag152-B16","doi-asserted-by":"crossref","first-page":"624102","DOI":"10.3389\/fendo.2021.624102","article-title":"Clinical prognostic factors in patients with metastatic adrenocortical carcinoma treated with second line gemcitabine plus capecitabine chemotherapy","volume":"12","author":"Grisanti","year":"2021","journal-title":"Front Endocrinol (Lausanne)"},{"issue":"15_suppl","key":"2026073109214794300_bvag152-B17","doi-asserted-by":"crossref","first-page":"e16591","DOI":"10.1200\/JCO.2018.36.15_suppl.e16591","article-title":"A retrospective analysis of carboplatin plus etoposide in patients with adrenal cortical carcinoma","volume":"36","author":"Campbell","year":"2018","journal-title":"J Clin Oncol"},{"issue":"6","key":"2026073109214794300_bvag152-B18","doi-asserted-by":"crossref","first-page":"681","DOI":"10.1530\/EJE-19-0570","article-title":"Activity and safety of temozolomide in advanced adrenocortical carcinoma patients","volume":"181","author":"Cosentini","year":"2019","journal-title":"Eur J Endocrinol"},{"issue":"7","key":"2026073109214794300_bvag152-B19","doi-asserted-by":"crossref","first-page":"2650","DOI":"10.1210\/jc.2005-2730","article-title":"Clinical and biological features in the prognosis of adrenocortical cancer: poor outcome of cortisol-secreting tumors in a series of 202 consecutive patients","volume":"91","author":"Abiven","year":"2006","journal-title":"J Clin Endocrinol Metab"},{"issue":"1","key":"2026073109214794300_bvag152-B20","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1186\/s40425-018-0424-9","article-title":"Avelumab in patients with previously treated metastatic adrenocortical carcinoma: phase 1b results from the JAVELIN solid tumor trial","volume":"6","author":"Le Tourneau","year":"2018","journal-title":"J Immunother Cancer"},{"issue":"1","key":"2026073109214794300_bvag152-B21","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1200\/JCO.19.01586","article-title":"PD-1 blockade in advanced adrenocortical carcinoma","volume":"38","author":"Raj","year":"2020","journal-title":"J Clin Oncol"},{"issue":"1","key":"2026073109214794300_bvag152-B22","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1186\/s40425-019-0722-x","article-title":"Phase II clinical trial of pembrolizumab efficacy and safety in advanced adrenocortical carcinoma","volume":"7","author":"Habra","year":"2019","journal-title":"J Immunother Cancer"},{"issue":"2","key":"2026073109214794300_bvag152-B23","doi-asserted-by":"crossref","first-page":"e001009","DOI":"10.1136\/jitc-2020-001009","article-title":"Combined lenvatinib and pembrolizumab as salvage therapy in advanced adrenal cortical carcinoma","volume":"8","author":"Bedrose","year":"2020","journal-title":"J Immunother Cancer"},{"issue":"5","key":"2026073109214794300_bvag152-B24","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1016\/S1470-2045(24)00095-0","article-title":"Cabozantinib monotherapy for advanced adrenocortical carcinoma: a single-arm, phase 2 trial","volume":"25","author":"Campbell","year":"2024","journal-title":"Lancet Oncol"},{"issue":"2","key":"2026073109214794300_bvag152-B25","doi-asserted-by":"crossref","first-page":"R105","DOI":"10.1530\/JME-18-0122","article-title":"Pathobiology and genetics of adrenocortical carcinoma","volume":"62","author":"Pittaway","year":"2019","journal-title":"J Mol Endocrinol"},{"issue":"1","key":"2026073109214794300_bvag152-B26","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1186\/s13046-021-02186-0","article-title":"Epigenetic activation of the elongator complex sensitizes gallbladder cancer to gemcitabine therapy","volume":"40","author":"Xu","year":"2021","journal-title":"J Exp Clin Cancer Res"},{"key":"2026073109214794300_bvag152-B27","doi-asserted-by":"crossref","first-page":"1152","DOI":"10.3389\/fonc.2020.01152","article-title":"Role of DNA methylation in the resistance to therapy in solid tumors","volume":"10","author":"Romero-Garcia","year":"2020","journal-title":"Front Oncol"}],"container-title":["Journal of the Endocrine Society"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/jes\/advance-article-pdf\/doi\/10.1210\/jendso\/bvag152\/68664861\/bvag152.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jes\/article-pdf\/10\/8\/bvag152\/68664861\/bvag152.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jes\/article-pdf\/10\/8\/bvag152\/68664861\/bvag152.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,31]],"date-time":"2026-07-31T13:21:54Z","timestamp":1785504114000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jes\/article\/doi\/10.1210\/jendso\/bvag152\/8722892"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,1]]},"references-count":27,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2026,7,8]]}},"URL":"https:\/\/doi.org\/10.1210\/jendso\/bvag152","relation":{},"ISSN":["2472-1972"],"issn-type":[{"value":"2472-1972","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026,8]]},"published":{"date-parts":[[2026,7,1]]},"article-number":"bvag152"}}